Vinay Prasad, a top regulator at the US Food and Drug Administration, has left the agency after a controversy over his ...

Indian-origin scientist Vinay Prasad resigned as the FDA's vaccine and gene therapy chief in just three months after backlash ...

Vinay Prasad, M.D., has left the FDA less than three months into the role as director of the Center for Biologics Evaluation ...

Vinay Prasad exits FDA's biologics division following pressure over Sarepta's Elevidys approval and regulatory controversies.

Dr. Vinay Prasad, a controversial figure and critic of the FDA, resigned from his high-ranking position at the agency after ...

This week on "The Readout LOUD," STAT's biotech reporters parse what Vinay Prasad's ouster means for biotech and the FDA.

Dr. Vinay Prasad has resigned from the FDA after less than three months amid controversy over Sarepta Therapeutics' gene ...

The U.S. Food and Drug Administration's top vaccine official, Vinay Prasad, has left the agency after just three months as ...

The immediate ebullient reaction to Vinay Prasad’s ouster is understandable, and may ultimately be the correct one, Adam ...

It is hard to imagine someone more equipped and more dedicated to vetting treatments than Vinay Prasad,” writes his former ...

The gene therapy chief wanted to block fast-track drug approvals.

Replimune (NASDAQ:REPL), and Capricor Therapeutics (NASDAQ:CAPR), which faced regulatory setbacks from the FDA’s biologics ...